Exploitation of Marine Molecules to Manage Alzheimer’s Disease

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéuticagl
dc.contributor.authorSilva, Marisa
dc.contributor.authorSeijas Villaverde, Paula
dc.contributor.authorOtero Fuertes, María Paz
dc.date.accessioned2021-07-30T12:04:03Z
dc.date.available2021-07-30T12:04:03Z
dc.date.issued2021
dc.description.abstractNeurodegenerative diseases are sociosanitary challenges of today, as a result of increased average life expectancy, with Alzheimer’s disease being one of the most prevalent. This pathology is characterized by brain impairment linked to a neurodegenerative process culminating in cognitive decline and behavioral disorders. Though the etiology of this pathology is still unknown, it is usually associated with the appearance of senile plaques and neurofibrillary tangles. The most used prophylaxis relies on anticholinesterase drugs and NMDA receptor antagonists, whose main action is to relieve symptoms and not to treat or prevent the disease. Currently, the scientific community is gathering efforts to disclose new natural compounds effective against Alzheimer’s disease and other neurodegenerative pathologies. Marine natural products have been shown to be promising candidates, and some have been proven to exert a high neuroprotection effect, constituting a large reservoir of potential drugs and nutraceutical agents. The present article attempts to describe the processes of extraction and isolation of bioactive compounds derived from sponges, algae, marine bacteria, invertebrates, crustaceans, and tunicates as drug candidates against AD, with a focus on the success of pharmacological activity in the process of finding new and effective drug compoundsgl
dc.description.peerreviewedSIgl
dc.description.sponsorshipP.O. would like to thank the Juan de la Cierva program of the Spanish Government (Ref. IJCI-2016-27774). M.S. would like to thank Fundação para a Ciência e a Tecnologia (FCT) for research funding via the VALTOX project under UIDB/04292/2020 and UID/MULTI/04046/2019 and was also supported by investigation contract under AQUA-PROSPECT project (MAR-02.02.01-FEAMP-0005)gl
dc.identifier.citationMar. Drugs 2021, 19(7), 373; https://doi.org/10.3390/md19070373gl
dc.identifier.doi10.3390/md19070373
dc.identifier.essn1660-3397
dc.identifier.urihttp://hdl.handle.net/10347/26663
dc.language.isoenggl
dc.publisherMDPIgl
dc.relation.publisherversionhttps://doi.org/10.3390/md19070373gl
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)gl
dc.rightsAtribución 4.0 Internacional
dc.rights.accessRightsopen accessgl
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAlzheimer’s diseasegl
dc.subjectMarine drugsgl
dc.subjectSpongesgl
dc.subjectAlgaegl
dc.subjectYieldsgl
dc.subjectNatural productsgl
dc.titleExploitation of Marine Molecules to Manage Alzheimer’s Diseasegl
dc.typejournal articlegl
dc.type.hasVersionVoRgl
dspace.entity.typePublication
relation.isAuthorOfPublication96f2fb3a-ac28-4dd4-85c4-60c8a2d6326a
relation.isAuthorOfPublication.latestForDiscovery96f2fb3a-ac28-4dd4-85c4-60c8a2d6326a

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021_marinedrugs_silva_exploitation.pdf
Size:
2.5 MB
Format:
Adobe Portable Document Format
Description: